Condition
Translocation Renal Cell Carcinoma
Total Trials
5
Recruiting
4
Active
5
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 1 (1)
P 2 (3)
Trial Status
Recruiting4
Active Not Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06835972Phase 1Recruiting
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
NCT06638931Phase 2Recruiting
Agnostic Therapy in Rare Solid Tumors
NCT07123090Phase 2Recruiting
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
NCT06318871Early Phase 1Recruiting
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
NCT04413123Phase 2Active Not Recruiting
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Showing all 5 trials